ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials
10.12.2019 11:00:00 EET | Business Wire | Press release
ImmunOs Therapeutics AG, a Swiss bio-technology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer, announced today the closing of a Series A financing of CHF 15 million. The round was co-led by the Basel life sciences venture capital firm BioMedPartners and Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), with the participation of Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd alongside new private and existing investors. The financing will be used to complete the first-in-human trials with the company’s lead agent, iosH2, a potential new cancer treatment for both solid and liquid tumors. The funding will also be used to broaden the company’s novel immunotherapy iosH platform by advancing additional preclinical programs focusing on both cancer and auto-immunity.
“Recent advances in the understanding of the innate immune system’s role in cancer provide a unique opportunity for ImmunOs Therapeutics and our partners. We value the ongoing support of all the current investors and welcome all the Series A round participants, specifically Pfizer Ventures and BioMedPartners, both of whom have demonstrated a strong commitment to the oncology field,” said Sean R. Smith, CEO of ImmunOs Therapeutics AG.
Dr. Osiris Marroquin Belaunzaran, CSO and co-founder, added: “It is with great pleasure to see that our early research based on HLA open conformer modulation of immune cells is advancing toward a clinical drug candidate for human studies. Targeting the innate immune system to modulate the tumor microenvironment has been a key strategy for ImmunOs, and together with foundational approaches targeting the adaptive immune system such as PD-1 antibodies, we aim to produce a strong therapeutic benefit in difficult-to-treat cancer indications."
In conjunction with the financing, ImmunOs Therapeutics has expanded its Board of Directors to include four new members: Dr. Markus Hosang of BioMedPartners; Dr. Michael Baran of Pfizer Inc.; Dr. Reinhard Ambros, former head Novartis Venture Fund; and Dr. Daniel Vasella, former Chairman and CEO Novartis.
Dr. Markus Hosang noted: “At BioMedPartners, we have over the last 15 years very successfully invested in and brought forward several innovative early-stage cancer companies. We got particularly attracted by ImmunOs and its novel approach that also adds to existing treatment modalities and thus has the potential to provide novel medicines to cancer patients who do not obtain a long-term benefit from current therapies.”
Dr. Michael Baran added: “Advances in understanding the role of the innate immune system is opening up opportunities to expand the potential of cancer immunotherapy. Pfizer Ventures is enthusiastic to support this emerging area through our investment in ImmunOs.”
About ImmunOs Therapeutics AG:
ImmunOs Therapeutics AG is a biotechnology company active in the discovery and development of the next generation of novel human immunomodulatory proteins focused on innate immunity. Originally a spin-off company of the University of Zurich and the University of Basel, our mission is to develop novel therapeutics that will improve the lives of patients with serious disease.
ImmunOs Therapeutics AG lead program is a next generation, novel platform of multitasking biologics targeting diverse immunoregulatory receptors that activate anti-tumor responses built upon years of research and development. ImmunOs proteins work directly on the innate immune system. (For more information, please visit www.immunostherapeutics.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005042/en/
Contact information
Investor Relations
Wagistrasse 14
8952 Schlieren (Zurich Area), Switzerland
info@immunostherapeutics.com
International Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 or +49 30 23 63 27 68
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
‘Concrete in Life 2025/26’ Winners Announced – Spectacular Photographs From Around the World22.4.2026 11:00:00 EEST | Press release
Powerful and striking images from around the world have been chosen as the winners of the Concrete in Life 2025/26 global photography competition, showcasing the essential role concrete plays in daily life, infrastructure, cities, and design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422352135/en/ OVERALL WINNER: Pillars Across the Sea by Celbert Palaganas, Cebu City, Philippines Run by the Global Cement and Concrete Association (GCCA), the annual competition received more than 20,000 entries from professional and amateur photographers, as well as smartphone users, spanning every continent. The competition highlights how concrete supports modern life while also offering moments of beauty, creativity and human connection. Thomas Guillot, Chief Executive of the GCCA, said: “The spectacular images submitted this year show concrete’s positive impact on people’s lives all over the world - sometimes practical, sometimes al
Netceed Publishes Its First Environmental, Social and Governance Report22.4.2026 10:30:00 EEST | Press release
Netceed, a global infrastructure supply chain solutions provider, has published our first Annual Environmental, Social and Governance (ESG) Report, marking a major milestone in the Group’s sustainability journey and reinforcing our commitment to transparency, accountability, and responsible business practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422579806/en/ Netceed Sustainability Report 2025 The report presents Netceed’s progress across environmental, social, and governance topics, including the verification of its carbon footprint data by an independent third party and the completion of its first climate risk analysis. Key highlights include: A reduction in Scope 1 and 2 CO2e emissions compared to 2024 Improved gender diversity in senior management positions – we now have 23% of senior management positions filled by women 70% of our suppliers (by spend) are working with us on our climate action priorities A
IONCHI toivottaa AITO:n tervetulleeksi liittymään BMW:n ja Mercedes-Benzin kanssa premium-tason suurteholatausverkostojen kehittämiseen Kiinassa22.4.2026 10:21:00 EEST | Tiedote
IONCHI, BMW:n ja Mercedes-Benzin yhteisyritys suurteholatauspalvelujen alalla, ilmoitti tänään, että SERES liittyy yhtiöön tasavertaisena osakkaana. Tämän omistusjärjestelyn kautta SERES-konsernin premium-brändi AITO tukee IONCHI:n premium-latausinfrastruktuurin kehittämistä. Tämän lisäyksen myötä IONCHI jatkaa korkealaatuisten latauspalvelujen tarjoamista kehittyneen teknologian ja digitaalisten palvelujen avulla kaikille soveltuville ajoneuvoille sekä tarjoaa eksklusiivisia latauskokemuksia BMW:n, AITO:n ja Mercedes-Benzin asiakkaille. Laajentunut kolmen osapuolen kumppanuus merkitsee uuden vaiheen alkua premium-latausverkoston kehityksessä, mahdollistaen lisäkasvun ja laajemman asiakaskunnan. Kukin kolmesta osakkaasta omistaa 33,3 % yhteisyrityksestä. Vuonna 2024 perustettu IONCHI pyrkii parantamaan Kiinan premium-tasoista sähköisen liikkumisen kokemusta huipputeknisen julkisen suurteholatausverkoston avulla. Verkosto keskittyy keskeisiin sijainteihin kaupunkialueilla yhdistäen ultr
Europcar Mobility Group Announces Exclusive Partnership With MIC Co., Ltd. to Expand Presence in Japan22.4.2026 10:02:00 EEST | Press release
Europcar Mobility Group has entered into an exclusive partnership agreement with MIC Co., Ltd., the operator of Japan’s extensive "Niconico Rent-A-Car" network. This landmark agreement marks Europcar Mobility Group’s first exclusive partnership in the Japanese market, aimed at providing seamless mobility solutions for the growing number of international travelers visiting the region. Enhancing possibilities for Inbound Travelers Since April 10, 2026, customers can book car rentals at Niconico Rent-A-Car’s directly-operated airport locations through Europcar’s global booking platform, allowing foreign travelers to arrange their transportation in Japan from overseas using a familiar interface, eliminating common booking hurdles and improving the overall travel experience.To date, the service is available across key gateway locations: Major Airports: Haneda, Narita, New Chitose, Fukuoka, Kagoshima, Nagasaki, and Kumamoto. Key Transit Hubs: Shin-Yokohama Station and Kansai Airport Rinku To
SkySparc Acquires Covarius and Uniun22.4.2026 10:00:00 EEST | Press release
SkySparc, a trusted global provider of digital transformation solutions for treasury and finance institutions, today announced the acquisition of Covarius Group Limited (“Covarius”) and Uniun Technology Limited (“Uniun”). The acquisitions accelerate SkySparc’s European expansion and deepen its specialist support for treasury transformation. Financial terms were not disclosed. Covarius and Uniun operate complementary businesses together enabling a more complete, end-to-end treasury solution. Covarius specialises in the implementation and optimisation of treasury management systems, underpinned by deep partnerships and a well-established global presence. Uniun adds a real-time, API-based integration platform focused on ERP-to-TMS connectivity and cash forecasting, supported by AI and data science. For clients, the combined proposition the two companies bring centres on improved cash visibility and stronger cash flow prediction, with greater automation across treasury workflows, improving
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom